Loading…
Relay Therapeutics, Inc. is projected to rise to $17.73 by 2027, a +23% move from its current price of $14.43. RLAY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.95 | $14.43 | $14.94 | +0.02% |
| May 30 | $13.75 | $14.44 | $15.15 | +0.04% |
| May 31 | $13.60 | $14.44 | $15.32 | +0.06% |
| Jun 1 | $13.48 | $14.44 | $15.47 | +0.08% |
| Jun 2 | $13.38 | $14.44 | $15.60 | +0.10% |
| Jun 3 | $13.28 | $14.45 | $15.72 | +0.12% |
| Jun 4 | $13.19 | $14.45 | $15.83 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.19 | $14.45 | $15.83 | +0.14% |
| Week 2 | $12.73 | $14.47 | $16.46 | +0.29% |
| Week 3 | $12.38 | $14.49 | $16.96 | +0.43% |
| Week 4 | $12.10 | $14.51 | $17.41 | +0.58% |
| Week 5 | $11.86 | $14.53 | $17.81 | +0.72% |
| Week 6 | $11.65 | $14.55 | $18.19 | +0.86% |
| Week 7 | $11.46 | $14.58 | $18.54 | +1.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Relay Therapeutics' lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer.
It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc.
for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc.
and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics, Inc. (RLAY) is a healthcare company that trades at $13.53 per share, with a market cap of $2.59B and a rank of 1833. The stock sits in a bullish technical context as of the current metrics, with a 30-day range from $10.74 to $17.05 and a nearby support at $12.07 and resistance at $16.80.
The near-term picture is complemented by a 50-day moving average of $12.79 and a 200-day moving average of $8.32, with RSI at 50. The longer-run forecast points to meaningful upside, with multi-year averages extending toward higher levels, including notable targets in 2030 and beyond.
A major floor 49.1% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
The nearest ceiling, 16.4% above — a clean break opens room to run.
A major ceiling 32.8% above — clearing it would confirm fresh momentum.
Key RLAY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLAY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.76 | Buy | $13.80 | Buy |
| MA 10 | $13.12 | Buy | $13.43 | Buy |
| MA 20 | $12.97 | Buy | $13.32 | Buy |
| MA 50 | $12.95 | Buy | $12.70 | Buy |
| MA 100 | $10.85 | Buy | $11.28 | Buy |
| MA 200 | $8.43 | Buy | $9.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.25 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 224.41 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 13.09 | Buy |
| Bollinger %B (20,2) | 1.11 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 76.56 | Sell |
| Momentum (10) | 1.50 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 14.42 | Buy |
| ADX (14) | 17.22 | Neutral |
| ATR (14) | 0.40 | Info |
The sentiment is BULLISH and RSI14 is 50. The stock trades near the 50-day moving average of $12.79 and well above the 200-day moving average of $8.32. The nearest support is $12.07 and the nearest resistance is $16.80. The 30-day price range spans from $10.74 to $17.05, illustrating a defined short-term trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.35 | $14.43 | $19.77 | 0% | Neutral | |
| $13.71 | $17.73 | $24.49 | +23% | Bullish | |
| $16.21 | $21.71 | $31.31 | +50% | Bullish | |
| $22.56 | $31.13 | $46.45 | +116% | Bullish | |
| $24.74 | $35.06 | $53.84 | +143% | Bullish | |
| $27.44 | $39.85 | $62.73 | +176% | Bullish | |
| $31.68 | $47.07 | $75.78 | +226% | Bullish | |
| $29.60 | $44.92 | $73.80 | +211% | Bullish | |
| $33.43 | $51.80 | $86.69 | +259% | Bullish | |
| $43.88 | $69.36 | $118.09 | +381% | Bullish | |
| $60.69 | $105.14 | $192.33 | +629% | Bullish | |
| $128.53 | $262.33 | $532.20 | +17.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.35 | $14.43 | $17.04 | +0.00% |
| June 2026 | $12.23 | $14.44 | $17.52 | +0.06% |
| July 2026 | $12.32 | $14.70 | $18.14 | +1.82% |
| August 2026 | $12.74 | $15.34 | $19.17 | +4.33% |
| September 2026 | $12.53 | $15.19 | $19.19 | -0.95% |
| October 2026 | $12.01 | $14.65 | $18.67 | -3.58% |
| November 2026 | $12.14 | $14.89 | $19.14 | +1.64% |
| December 2026 | $12.37 | $15.26 | $19.77 | +2.50% |
Click any year to see its month-by-month RLAY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RLAY could reach as high as $19.77, with a base case around $14.43 and support toward $7.35 — roughly 0% from $14.43. A consolidation phase looks the most probable path here.
Expect RLAY to range from $13.71 to $24.49 through 2027. The $17.73 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Momentum favours further upside here.
The RLAY price prediction for 2028 points to an average of $21.71 (low $16.21, high $31.31) — a potential gain of +50% on today's $14.43. Buyers look set to stay in control over this stretch.
In 2029, RLAY is projected to trade between $22.56 and $46.45, averaging $31.13 — a potential gain of +116% from today's $14.43. That is up +43% on the projected 2028 average. Momentum favours further upside here.
Relay Therapeutics, Inc.'s 2030 outlook centres on $35.06, within a $24.74 to $53.84 range. That is up +13% on the projected 2029 average. That marks a +143% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RLAY could reach as high as $62.73, with a base case around $39.85 and support toward $27.44 — roughly +176% from $14.43. Momentum favours further upside here.
Expect RLAY to range from $31.68 to $75.78 through 2032. The $47.07 average target implies a +226% move from current prices. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RLAY price prediction for 2033 points to an average of $44.92 (low $29.60, high $73.80) — a potential gain of +211% on today's $14.43. Momentum favours further upside here.
In 2034, RLAY is projected to trade between $33.43 and $86.69, averaging $51.80 — a potential gain of +259% from today's $14.43. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Relay Therapeutics, Inc.'s 2035 outlook centres on $69.36, within a $43.88 to $118.09 range. That is up +34% on the projected 2034 average. That marks a +381% change versus current levels. Momentum favours further upside here.
By 2040, RLAY could reach as high as $192.33, with a base case around $105.14 and support toward $60.69 — roughly +629% from $14.43. Buyers look set to stay in control over this stretch.
Expect RLAY to range from $128.53 to $532.20 through 2050. The $262.33 average target implies a +17.2x move from current prices. That is up +150% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RLAY today (≈ 69.300069 RLAY) could be worth
$18,179.81
+$17,179.81 (+1718%) by 2050 · US Dollar
Based on the average projected RLAY price of $262.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLAYwould be worth at today's price.
$1,000 invested in RLAY on May 27, 2025 (≈ 350.877205 RLAY) would be worth
$5,063.16
+$4,063.16 (+406.3%) today · 5.06× · US Dollar
Based on a RLAY entry price of $2.85 vs. today's $14.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.02 | $1,108.29 | +10.8% |
| 1 month ago | $14.95 | $965.22 | -3.5% |
| 3 months ago | $9.16 | $1,575.33 | +57.5% |
| 6 months ago | $7.92 | $1,821.97 | +82.2% |
| 1 year ago | $2.85 | $5,063.16 | +406.3% |
| All time (5.0y) ago | $32.66 | $441.82 | -55.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLAY forecast.
Our base-case forecast reaches $29.00 around 2029.
Implied market cap at $29.00: $6.32B
The multi-year forecast shows a rising trajectory in average price and upside potential. In 2026, the average is $13.53 with ROI 0 and sentiment NEUTRAL. By 2027, the average is projected to $16.68 with ROI 23.3 and a bullish tone, followed by $20.52 (51.7 ROI) in 2028 and $29.35 (117 ROI) in 2029.
The path continues to 2030 with an average of $33.44 (147.2 ROI) and a bullish sentiment, then higher in 2031 at $38.52 (184.7 ROI) and 2032 at $45.19 (234 ROI). The pattern persists into 2033 at $42.90 (217.1 ROI) and 2034 at $49.96 (269.3 ROI), 2035 at $66.65 (392.6 ROI). The long-range view reaches $102.88 (660.4 ROI) in 2040 and $257.07 (1800 ROI) in 2050, with bullish sentiment in both years.
These figures are estimates and not guarantees, and reflect higher potential upside alongside notable risk and volatility.
Tap a question to reveal the answer.
Avg $33.44, ROI 147.2, sentiment BULLISH.
Forecasts show rising averages and bullish sentiment in multiple years (e.g., 2027 avg $16.68, 2028 $20.52, 2029 $29.35, 2030 $33.44, 2040 $102.88, 2050 $257.07); these are estimates and not guarantees.
Yes, the forecast for 2040 shows an average price of $102.88, indicating potential above $100 in the long term.
Current price $13.53; market cap $2.59B.
The 30-day range is $10.74 to $17.05.
Relay Therapeutics, Inc. Community Discussion
0Share your Relay Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.